AIM2 as a therapeutic target in autoimmunity: balancing inflammasome inhibition with immune homeostasis.

Xu WD, Liu Z, Su LC, Huang AF

Open source

DOI
10.1016/j.autrev.2026.104218
Published
2026 Oct 24
Container
Autoimmunity reviews
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.autrev.2026.104218,
  title = {AIM2 as a therapeutic target in autoimmunity: balancing inflammasome inhibition with immune homeostasis.},
  author = {Xu WD and Liu Z and Su LC and Huang AF},
  year = {2026},
  journal = {Autoimmunity reviews},
  doi = {10.1016/j.autrev.2026.104218},
  url = {https://doi.org/10.1016/j.autrev.2026.104218}
}

RIS

TY  - JOUR
TI  - AIM2 as a therapeutic target in autoimmunity: balancing inflammasome inhibition with immune homeostasis.
AU  - Xu WD
AU  - Liu Z
AU  - Su LC
AU  - Huang AF
PY  - 2026
JO  - Autoimmunity reviews
DO  - 10.1016/j.autrev.2026.104218
UR  - https://doi.org/10.1016/j.autrev.2026.104218
ER  - 

APA

WD, X., Z, L., LC, S., & AF, H. (2026). AIM2 as a therapeutic target in autoimmunity: balancing inflammasome inhibition with immune homeostasis.. Autoimmunity reviews. https://doi.org/10.1016/j.autrev.2026.104218

Source records